You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 16, 2025

Details for Patent: 7,785,627


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,785,627
Title:Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Abstract:A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.
Inventor(s): Kositprapa; Unchalee (Davie, FL), Goldfarb; Robert I. (Golden Beach, FL), Cardinal; John (Tamarac, FL), Nangia; Avinash (Weston, FL)
Assignee: Watson Pharmaceuticals, Inc. (Corona, CA)
Application Number:10/664,803
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Device;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 7,785,627: A Comprehensive Analysis

Introduction

Patent US-7785627-B2, titled "Pharmaceutical formulation containing a biguanide and a sulfonylurea," is a significant patent in the pharmaceutical industry. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent.

Background of the Patent

The patent in question, US-7785627-B2, was granted for a pharmaceutical formulation that combines a biguanide (such as metformin) and a sulfonylurea. This combination is used to treat type 2 diabetes mellitus. The patent describes the formulation, its method of preparation, and its therapeutic uses[4].

Scope of the Patent

Therapeutic Use

The patent specifies the therapeutic use of the formulation, which is primarily for the treatment of type 2 diabetes. The combination of a biguanide and a sulfonylurea is designed to enhance the efficacy of diabetes treatment by addressing different aspects of the disease.

Formulation Details

The patent provides detailed descriptions of the pharmaceutical formulation, including the ratio of biguanide to sulfonylurea, the excipients used, and the method of administration. This specificity is crucial for ensuring that the formulation meets the required standards for safety and efficacy.

Claims of the Patent

Independent Claims

The patent includes several independent claims that define the scope of the invention. These claims typically cover the composition of the formulation, the method of preparing it, and the method of using it for therapeutic purposes.

Dependent Claims

Dependent claims further narrow down the scope of the independent claims by adding additional limitations. For example, dependent claims might specify particular ratios of the active ingredients, specific excipients, or particular methods of administration.

Patent Landscape

Related Patents

The patent landscape for pharmaceutical formulations involving biguanides and sulfonylureas is complex. There are numerous patents that cover various aspects of these formulations, including different combinations of active ingredients, different methods of preparation, and different therapeutic uses. Understanding these related patents is essential for avoiding infringement and identifying potential licensing opportunities.

Patent Trolls and Litigation

The pharmaceutical industry is not immune to the issue of patent trolls, which can significantly impact innovation. Patent trolls often acquire patents not to use them but to enforce them against other companies. This can lead to costly litigation and hinder the development of new treatments. Efforts to combat patent trolls, such as the anti-patent troll laws supported by various Attorneys General, are crucial for maintaining a healthy innovation environment[2].

Quality of Patent Applications

The quality of patent applications, including those related to pharmaceutical formulations, is a critical issue. The USPTO has been working to improve patent quality through initiatives such as the Enhanced Patent Quality Initiative. This includes defining patent quality more consistently, reassessing examination times, and analyzing the effects of incentives on patent quality. Clear and concise language in patent applications is essential, and tools like glossaries of key terms can help ensure that patents meet statutory requirements[1].

Small Claims Patent Court

There have been discussions and studies on the feasibility of a small claims patent court, which could impact how patent disputes, including those related to pharmaceutical formulations, are handled. Such a court would aim to provide a more efficient and cost-effective way to resolve patent disputes, particularly for smaller entities[5].

Economic and Research Implications

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset provides valuable insights into patent claims, including those related to pharmaceutical formulations. This dataset can help researchers and practitioners understand trends in patent scope and the dependency relationships between claims. It is a powerful tool for analyzing the patent landscape and making informed decisions about patent strategy[3].

Economic Impact

The economic impact of patents in the pharmaceutical industry is significant. Patents can drive innovation by providing exclusive rights to inventors, which can lead to substantial economic benefits. However, they must be balanced with the need for public access to life-saving treatments. The scope and claims of patents like US-7785627-B2 play a crucial role in this balance.

Key Takeaways

  • Therapeutic Use: The patent is specifically for the treatment of type 2 diabetes mellitus using a combination of a biguanide and a sulfonylurea.
  • Formulation Details: The patent includes detailed descriptions of the formulation, including ratios of active ingredients and methods of preparation.
  • Patent Landscape: The landscape is complex, with numerous related patents and the potential for patent troll activity.
  • Patent Quality: Ensuring high-quality patent applications is crucial, and initiatives by the USPTO aim to improve this.
  • Small Claims Court: Discussions on a small claims patent court could change how patent disputes are resolved.
  • Economic Impact: Patents in the pharmaceutical industry have significant economic implications and must balance innovation with public access.

FAQs

What is the main therapeutic use of the formulation described in US-7785627-B2?

The main therapeutic use is the treatment of type 2 diabetes mellitus.

How does the USPTO ensure the quality of patent applications?

The USPTO has initiatives such as the Enhanced Patent Quality Initiative, which includes defining patent quality consistently, reassessing examination times, and analyzing the effects of incentives on patent quality.

What is the role of a small claims patent court in the patent landscape?

A small claims patent court would provide a more efficient and cost-effective way to resolve patent disputes, particularly for smaller entities.

How do patent trolls affect innovation in the pharmaceutical industry?

Patent trolls can hinder innovation by enforcing patents against other companies, leading to costly litigation and diverting resources away from research and development.

What is the significance of the Patent Claims Research Dataset?

The dataset provides detailed information on claims from U.S. patents and applications, helping researchers and practitioners understand trends in patent scope and dependency relationships between claims.

Sources

  1. GAO Report: Intellectual Property: Patent Office Should Define Quality, Reassess Time Allotted for Examination, and Analyze Incentives.
  2. NCDOJ: Attorney General Josh Stein Leads Coalition Fighting Against Patent Trolls.
  3. USPTO: Patent Claims Research Dataset.
  4. PubChem: Pharmaceutical formulation containing a biguanide and a sulfonylurea.
  5. ACUS: U.S. Patent Small Claims Court.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 7,785,627

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
Takeda Pharms Usa ACTOPLUS MET XR metformin hydrochloride; pioglitazone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022024-001 May 12, 2009 DISCN Yes No 7,785,627 ⤷  Try for Free Y ⤷  Try for Free
Takeda Pharms Usa ACTOPLUS MET XR metformin hydrochloride; pioglitazone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022024-002 May 12, 2009 DISCN Yes No 7,785,627 ⤷  Try for Free Y ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 1 to 2 of 2 entries

International Family Members for US Patent 7,785,627

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Argentina 054238 ⤷  Try for Free
Australia 2003272504 ⤷  Try for Free
Australia 2004283059 ⤷  Try for Free
Australia 2006232993 ⤷  Try for Free
Australia 2011202162 ⤷  Try for Free
Brazil PI0414471 ⤷  Try for Free
Brazil PI0609550 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 7 of 7 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.